CYP2C9与KCNJ11基因多态性对2型糖尿病患者格列美脲降血糖效果的影响

Effect of CYP2C9 and KCNJ11 Genes Polymorphisms on Glucose-Lowering Effect of Glimepiride in Patients with Type 2 Diabetes Mellitus

目的探讨CYP2C9与KCNJ11基因多态性对2型糖尿病患者格列美脲降血糖效果的影响。方法选取医院2016年6月至2020年5月收治的2型糖尿病患者102例,均口服格列美脲12周,计算服用格列美脲前后空腹血糖(FBG)与糖化血红蛋白(HbA_(1C))水平下降值。采用Sanger测序法测定CYP2C9基因多态性CYP2C9*2(rs1799853),CYP2C9*3(rs1057910)与KCNJ11基因多态性E23K(rs5219)。结果野生型CYP2C9*1/*1与突变型CYP2C9*1/*3间FBG和HbA_(1C)水平下降值均无显著差异(P>0.05);KCNJ11E/E,E/K,K/K基因型间FBG和HbA_(1C)水平下降值亦无显著差异(P>0.05)。结论CYP2C9*1/*3与KCNJ11 E23K基因多态性不影响2型糖尿病患者格列美脲的降血糖效果。

Objective To investigate the effect of CYP2 C9 and KCNJ11 genes polymorphisms on the glucose-lowering effect of glimepiride in patients with type 2 diabetes mellitus(T2 DM).Methods A total of 102 patients with T2 DM admitted to our hospital from June 2016 to May 2020 were selected.All patients were treated with glimepiride for 12 weeks.The reduction levels of fasting blood glucose(FBG)and glycosylated haemoglobin(HbA1 C)before and after glimepiride treatment were calculated.The CYP2 C9 gene polymorphism CYP2 C9*2(rs1799853),CYP2 C9*3(rs1057910)and KCNJ11 gene polymorphism E23 K(rs5219)were determined by the Sanger sequencing method.Results There was no significant difference in the reduction levels of FBG and HbA1 C between wild-type CYP2 C9*1/*1 and mutant CYP2 C9*1/*3(P>0.05).Also no significant difference was found in the reduction levels of FBG and HbA1 C among KCNJ11 E/E,E/K and K/K genotypes(P>0.05).Conclusion CYP2 C9*1/*3 and KCNJ11 E23 K gene polymorphisms do not affect glucose-lowering effect of glimepiride in patients with T2 DM.